Anixa Biosciences, Inc. (ANIX) financial statements (2021 and earlier)

Company profile

Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE, CA 95118
State of Incorp. DE
Fiscal Year End October 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:14965737
Cash and cash equivalents12633324
Short-term investments2322412
Other undisclosed cash, cash equivalents, and short-term investments   0(0)(0)(0)
Receivables 00    
Other undisclosed current assets1000000
Total current assets:15966737
Noncurrent Assets
Operating lease, right-of-use asset00 
Property, plant and equipment  00000
Intangible assets, net (including goodwill)  (2)(2)(1)(1)(1)
Intangible assets, net (excluding goodwill)  (2)(2)(1)(1)(1)
Other undisclosed noncurrent assets 022333
Total noncurrent assets:0001222
TOTAL ASSETS:15966969
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111100
Accounts payable1011000
Accrued liabilities1111000
Employee-related liabilities     0 
Other undisclosed current liabilities00    0
Total current liabilities:2111101
Noncurrent Liabilities
Other undisclosed noncurrent liabilities     44
Total noncurrent liabilities:     44
Total liabilities:2111154
Stockholders' equity
Stockholders' equity attributable to parent14955815
Preferred stock     00
Common stock0000000
Additional paid in capital207200187175164152151
Accumulated deficit(194)(192)(182)(170)(156)(151)(146)
Stockholders' equity attributable to noncontrolling interest(1)(0)(0)(0)   
Total stockholders' equity:13855815
TOTAL LIABILITIES AND EQUITY:15966969

Income statement (P&L) ($ in millions)

1/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
Revenues1 01009
Revenue, net 09
Cost of revenue(4)(4)(0)(2)(0)(0) 
Gross profit:(4)(4)0(1)0(0)9
Operating expenses(6)(6)(12)(13)(6)(4)(10)
Other undisclosed operating income      0
Operating loss:(10)(10)(12)(14)(6)(5)(1)
Nonoperating income (expense)(0) 00000
Investment income, nonoperating0 00000
Other nonoperating expense(0)      
Interest and debt expense(0)   1(1)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Loss before gain (loss) on sale of properties:(10)(10)(12)(14)(5)(5)(1)
Other undisclosed net loss(0)(0)     
Net loss:(10)(10)(12)(14)(5)(5)(1)
Net income attributable to noncontrolling interest0000   
Other undisclosed net loss attributable to parent    (2)  
Net loss available to common stockholders, diluted:(10)(10)(12)(14)(7)(5)(1)

Comprehensive Income ($ in millions)

1/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
Net loss:(10)(10)(12)(14)(5)(5)(1)
Comprehensive loss:(10)(10)(12)(14)(5)(5)(1)
Comprehensive income, net of tax, attributable to noncontrolling interest0000   
Comprehensive loss, net of tax, attributable to parent:(10)(10)(12)(14)(5)(5)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: